BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...
Ensoma’s lead program, EN-374, represents the first in vivo HSC-directed therapy for X-CGD, building on a mechanism that has been validated ex vivo. About Ensoma Ensoma is developing potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback